ALLO - Company ID 0001737287
The table below shows Allogene Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $38.63M | $30.31M | $37.81M | $52.33M | $42.45M | $51.24M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $340.00M |
| $273.29M |
| $260.72M |
| $282.65M |
| $291.58M |
| $304.42M |
| Property, plant & equipment | $67.38M | $70.02M | $75.90M | $78.86M | $82.99M | $88.99M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $550.09M | $395.96M | $439.77M | $470.59M | $507.98M | $589.12M |
| Accounts payable | $5.96M | $4.93M | $3.70M | $4.85M | $5.06M | $5.51M |
| Total current liabilities | $31.73M | $28.33M | $31.83M | $31.68M | $30.02M | $32.57M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $113.92M | $117.08M | $124.44M | $126.03M | $122.59M | $125.37M |
| Retained earnings | -$2.10B | -$2.05B | -$1.97B | -$1.93B | -$1.88B | -$1.76B |
| Total equity | $436.18M | $278.88M | $315.33M | $344.56M | $385.39M | $463.75M |